Nuvalent (NUVL) Projected to Post Quarterly Earnings on Thursday

Nuvalent (NASDAQ:NUVL) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Nuvalent to post earnings of ($1.48) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Nuvalent Stock Up 2.5%

NASDAQ:NUVL opened at $103.00 on Tuesday. The firm’s fifty day simple moving average is $103.37 and its 200 day simple moving average is $94.52. The stock has a market cap of $7.49 billion, a P/E ratio of -19.36 and a beta of 1.32. Nuvalent has a twelve month low of $55.53 and a twelve month high of $113.01.

Insider Activity

In other Nuvalent news, CFO Alexandra Balcom sold 3,181 shares of Nuvalent stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $97.16, for a total value of $309,065.96. Following the completion of the sale, the chief financial officer owned 81,733 shares of the company’s stock, valued at approximately $7,941,178.28. The trade was a 3.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James Richard Porter sold 9,543 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $97.16, for a total value of $927,197.88. Following the completion of the transaction, the chief executive officer owned 278,629 shares in the company, valued at approximately $27,071,593.64. This trade represents a 3.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 76,463 shares of company stock worth $7,722,489. 10.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. US Bancorp DE raised its position in shares of Nuvalent by 10.0% during the third quarter. US Bancorp DE now owns 2,070 shares of the company’s stock valued at $179,000 after buying an additional 188 shares during the last quarter. Portland Investment Counsel Inc. bought a new position in shares of Nuvalent during the fourth quarter worth $201,000. FORA Capital LLC purchased a new position in Nuvalent during the fourth quarter valued at $218,000. Tower Research Capital LLC TRC increased its holdings in Nuvalent by 23.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,142 shares of the company’s stock valued at $240,000 after acquiring an additional 588 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new stake in Nuvalent in the 4th quarter valued at $251,000. Institutional investors own 97.26% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on NUVL. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd. HC Wainwright upped their target price on Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Wedbush restated an “outperform” rating and issued a $125.00 target price (up previously from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. Barclays set a $152.00 price target on Nuvalent in a research report on Monday, November 17th. Finally, The Goldman Sachs Group increased their price objective on Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Fifteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Nuvalent has a consensus rating of “Moderate Buy” and an average target price of $138.33.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.